AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13DBratton Douglas K • December 29th, 2014 • Biological products, (no disgnostic substances)
Each of the undersigned hereby acknowledges and agrees, pursuant to the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit, and any amendments thereto, with respect to the beneficial ownership of the undersigned of shares Juno Therapeutics, Inc., will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned.
LOCK-UP LETTERBratton Douglas K • December 29th, 2014 • Biological products, (no disgnostic substances)
